toxylact: a05ab01 nicotinyl methylamide

The first professional lActological database in the word

Nicotinyl methylamide (ATC A05AB01) is a biliary tract medicine used in the treatment of diseases affecting the bile ducts, with toxicological and lactation safety assessed in the context of hepatobiliary function and infant exposure.medpedia.framar

ATC position and pharmacological nature

Nicotinyl methylamide is classified in the ATC system as A05AB01, within the subgroup of preparations for biliary tract therapy (A05AB) and the broader group of drugs for biliary tract and liver diseases (A05).medpedia.framar
It is described as a metabolite of nicotinamide, linking it structurally to vitamin B3–related compounds, but used specifically for bile duct pathology rather than as a nutritional supplement.medpedia.framar
The medicinal product is positioned for symptomatic and disease-modifying management in biliary tract disorders, where modulation of biliary function and improvement of bile flow are desired therapeutic goals.

Indications and contraindications

The primary indication of nicotinyl methylamide is “diseases of the biliary tract,” a collective term covering disorders that structurally or functionally affect the extrahepatic bile ducts.medpedia.framar
Typical clinical scenarios include inflammatory or obstructive biliary disease, where supporting bile flow and duct function may relieve symptoms such as cholestatic pain and digestive disturbances.
It is contraindicated in patients with hypersensitivity to nicotinyl methylamide or any excipients in the medicinal product, and treatment must be discontinued if allergic reactions are suspected.medpedia.framar

Toxicological considerations

As a metabolite of nicotinamide, nicotinyl methylamide is expected to share some features of the parent compound, but its targeted use in bile duct disease requires specific toxicological vigilance.medpedia.framar
Potential risks relate to idiosyncratic hypersensitivity, altered pharmacokinetics in severe hepatic or biliary obstruction, and cumulative exposure in patients with compromised elimination.
Clinical monitoring should therefore include liver function tests, evaluation for worsening cholestasis, and observation for cutaneous or systemic allergic manifestations during therapy.

Lactation safety profile

In breastfeeding women, nicotinyl methylamide must be evaluated in light of maternal hepatobiliary status, since cholestasis and bile duct obstruction can alter drug distribution and elimination.
Physicochemical properties inherited from nicotinamide metabolism, such as relative water solubility and moderate molecular size, suggest some potential for transfer into breast milk, but the actual infant dose will depend on maternal pharmacokinetics and dosage regimen.
Until robust clinical data in lactating women are available, expert practice would be to use nicotinyl methylamide in breastfeeding only when clearly indicated, with preference for short-term courses, minimal effective dose, and systematic observation of the infant for signs of gastrointestinal or cholestatic disturbance.

Clinical use and monitoring in breastfeeding

When nicotinyl methylamide is prescribed to a breastfeeding mother, the therapeutic decision should balance the severity of biliary tract disease against the theoretical risk of infant exposure.
Breastfed infants of treated mothers should be monitored for changes in feeding, stool colour or consistency, unexplained irritability or jaundice-like symptoms, which may indicate clinically relevant systemic exposure.
In cases of high-dose therapy, prolonged use or severe maternal hepatobiliary impairment, temporary interruption of breastfeeding or substitution with expressed milk from drug-free intervals can be considered after specialist consultation, especially in neonates and preterm infants.

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.